Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Evotec SE

Navigating SG&A Expenses: AstraZeneca PLC vs. Evotec SE

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Over the past decade, AstraZeneca PLC and Evotec SE have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have seen a significant increase of approximately 35%, peaking in 2022. This reflects their aggressive expansion and marketing strategies. In contrast, Evotec SE, a smaller player, has maintained a more conservative approach, with their SG&A expenses growing by nearly 840% over the same period, albeit from a much smaller base. This disparity highlights the different scales and strategies of these companies. As AstraZeneca continues to invest heavily in its global operations, Evotec's steady growth underscores its focus on sustainable expansion. Understanding these trends offers valuable insights into the financial strategies of leading pharmaceutical companies.